ASH 2024 Review: Key Updates in Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

M. Gallogly

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ASH & ISHL 2024 Summary: Key Clinical Questions & Highlights in cHL

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

ASH 2024 Treatment Updates in Lymphoma: Practice Changing and Promis…

UChicago Medicine

A. Rojek

High-Risk MCL: Recognition, Treatment, and Challenges

Preetesh Jain

ASH 2025 Review: Key Trials and Takeaways in 1L and R/R Follicular L…

University of Colorado Division of Hematology

T. Phillips

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson